Providers' payment and delivery system reforms hold both threats and opportunities for the drug and device industries

Health Affairs

Volumn 31, Issue 9, 2012, Pages 2059-2067

  Robinson, James C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE STUDY; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HOSPITAL PLANNING; HUMAN; MEDICAL DEVICE; MEDICAL FEE; MEDICAL TECHNOLOGY; PEER REVIEW; REIMBURSEMENT;

COST CONTROL; DRUG INDUSTRY; EQUIPMENT AND SUPPLIES; HEALTH CARE REFORM; HEALTH PERSONNEL; INSURANCE, HEALTH, REIMBURSEMENT; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 84871887221     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0401     Document Type: Article

References (41)

1. Meier B. Costs surge for medical devices, but benefits are opaque. New York Times. 2009 Nov 5.
2. Schneller E, Montgomery K. Hospital's strategies for orchestrating selection of physician preference items. Milbank Q. 2007;85(2): 307-35.
3. Robinson JC. Value-based purchasing of medical devices. Health Aff (Millwood). 2008;27(6):1523-31.
4. Weaver C. Study: hospitals overpay for devices. Wall Street Journal. 2012 Feb 3.
5. Steinbrook R, Ross J. "Transparency reports" on industry payments to physicians and teaching hospitals. JAMA. 2012;307(10):1029-30.
6. Robinson JC, Pozen A, Tseng S, Bozic KJ. Variability in costs associated with total hip and knee replacement implants. J Bone Jt Surg. Forthcoming 2012.
7. Dolan EL, Robinson JC. Coronary angioplasty with drug eluting stents: device costs, hospital costs, and insurance payments. Berkeley (CA): University of California, Berkeley, Center for Health Technology; 2010 Sep. (Issue Brief).
8. Dolan EL, Robinson JC. Volumes, costs, and reimbursement for cervical fusion surgery in California hospitals, 2008. Berkeley (CA): University of California, Berkeley, Center for Health Technology; 2010 Jul. (Issue Brief).
9. Greenberg B, Wynn P. Navigating the new era of technology assessment. Washington (DC): Advisory Board Company; 2010 Apr 6.
10. Boston Scientific Neurovascular Group. Device carve-out guide: insurer contracting for neuroendovascular implantables. Minneapolis (MN): Boston Scientific Corporation; 2005.
11. Robinson J. Hospitals respond to Medicare payment shortfalls by both shifting costs and cutting them, based on market concentration. Health Aff (Millwood). 2011;30(7): 803-12.
12. Genentech. The 2012 Genentech oncology trend report. 4th ed. South San Francisco (CA): Genentech; 2011.
13. Stefanacci RG. "B" isn't always for biologics. Manag Care. 2012;21(2): 50-4.
14. Express Scripts. 2011 drug trend report [Internet]. St. Louis (MO): Express Scripts; c2012 [cited 2012 Aug 1]. Available from: http:// digital.turn-page.com/i/70797
15. Pollack A. For profit, industry seeks cancer drugs. New York Times. 2009 Sep 2.
16. Silverman E. Setting the bar higher for off-label use of biologics. Biotechnol Healthc. 2011;8(3):14-8.
17. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006; 24(19):3206-8.
18. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology. Ann Oncol. 2007;18:1923-5.
19. National Comprehensive Cancer Network. Managed care and medical oncology: cancer is now on the table. Fort Washington (PA): NCCN; 2009. (Oncology Insights Report No. 1).
20. Butcher L. Will clinical pathways work? Biotechnol Healthc. 2010; 7(3):16-20.
21. Newcomer LN. Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood). 2012;31(4):780-5.
22. Jacobson M, Earle CC, Price M, Newhouse JP. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood). 2010; 29(7):1391-9.
23. Academy of Managed Care Pharmacy Task Force on Drug Payment Methodologies. AMCP guide to pharmaceutical payment methods, comprehensive edition, version 1.0 [Internet]. Alexandria (VA): AMCP; 2007 Oct [cited 2012 Aug 1]. Available from: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9856
24. Edelman B. Specialty pharmacy booms, but for how long? Biotechnol Healthc. 2004;1(1):32-7.
25. McKain J. Connecting patients with specialty products: distribution models for biologics and other specialty pharmaceutical products. Biotechnol Healthc. 2012;9(2):8-13.
26. Fitch K, Pyensen B. Site of service cost differences for Medicare patients receiving chemotherapy. New York (NY): Milliman; 2011 Oct 19.
27. Avalere Health. Total cost of cancer care by site of service: physician office vs outpatient hospital. Washington (DC): Avalere Health; 2012 Mar.
28. Keough CL, Webster SA. 340B program presents opportunities-and challenges. Healthc Finan Manag J. 2009;63(11):42-8.
29. Ranawat AS, Koenig JH, Thomas AJ, Drna CD, Shapiro LA. Aligning physician and hospital incentives: the approach at hospital for special surgery. Clin Orthop Relat Res. 2009;467(10):2535-41.
30. Wilensky GR, Wolter N, Fischer MM. Gain sharing: a good concept getting a bad name? Health Aff (Millwood). 2007;26(1):w58-67. DOI: 10.1377/ hlthaff.26.1.w58.
31. Ketcham JD, Furukawa MF. Hospital-physician gain sharing in cardiology. Health Aff (Millwood). 2008; 27(3):803-12.
32. Gutowski C, Ma J, Hoo KS, Bozic KJ. Health technology assessment at the University of California-San Francisco. J Healthc Manag. 2011;56(1): 15-29.
33. Butcher L. Employers struggle to cope with the rising use of biologics. Biotechnol Healthc. 2011;8(4):21-4.
34. Tu H, Samuel DR. Limited options to manage specialty drug spending. Washington (DC): Center for Studying Health System Change; 2012 Apr. (Research Brief No. 22).
35. Holcombe D. What payers and physicians need to look for in clinical pathways. Lyceum Newsletter Perspectives [serial on the Internet]. 2010 Aug 2 [cited 2012 Aug 1]. Available from: http://www.lyceum associates.com/Newsletter/Sample Articles/tabid/867/smid/2530/ArticleID/659/reftab/777/t/What-Payers-and-Physicians-Need-to-Look-for-in-Clinical-Pathways/Default.aspx
36. Smith TJ, Hilner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364:2060-5.
37. Bach PB, Mirkin JN, Luke JJ. Episode-based payment for cancer care: a proposed pilot for Medicare. Health Aff (Millwood). 2011;30(3): 500-9.
38. Ayala D, Woo A. Oncology case rate: overview [Internet]. San Ramon (CA): Hill Physicians Medical Group; [cited 2012 Aug 2]. Available from: http://www.ehcca.com/presentations/pfpsummit7/2.7_2.pdf
39. Chilukuri S, Gordon M, Musso C, Ramaswamy S. Design to value in medical devices [Internet]. Florham Park (NJ): McKinsey and Company; 2010 [cited 2012 Aug 2]. Available from: http://www.mckinsey.com/~/ media/mckinsey/dotcom/client_service/Pharma%20and%20 Medical%20Products/PMP%20 NEW/PDFs/774172_Design_to_value_in_medical_devices1.ashx
40. Nelson RR, Buterbaugh K, Perl M, Gelijns A. How medical know-how progresses. Research Pol. 2011; 40(10):1339-44.
41. Challoner DR, Vodra W. Medical devices and health-creating a new regulatory framework for moderaterisk devices. N Engl J Med. 2011; 365(11):977-9.